Arcus Biosciences’ casdatifan data challenge assumptions about HIF-2α inhibition in kidney cancer. Explore what changes next and what risks remain.
Gilead Sciences’ acquisition of Arcellx signals a strategic shift in CAR T therapy control and scale. Find out what it changes for multiple myeloma.
SylamoreBio partners with Daiichi Sankyo to test SyLEC CNS delivery technology. Find out what this collaboration changes for brain drug development.
EU approves subcutaneous amivantamab for expanded EGFR lung cancer dosing. Discover what this changes for clinicians and health systems.
PharmAla will generate three year stability data for LaNeo MDMA. Discover how this could shape packaging, regulation, and commercialization.
Novo Nordisk A/S disclosed headline Phase 3 data from the REDEFINE 4 trial showing that CagriSema, its fixed-dose combination of cagrilintide and semaglutide, achieved 23 percent weight loss over 84 weeks in people with obesity but failed to meet the primary endpoint of non-inferiority versus tirzepatide. The open-label head-to-head study compared once-weekly CagriSema 2.4 mg/2.4
Sōlaria Biō validates gut delivery and control of Bōndia microbes. Read what the study really means for bone health and medical foods.
Find out how zenocutuzumab treatment beyond progression could change care for NRG1 fusion-positive lung cancer and what clinicians should watch next.
Explore what PureHealth Research’s lymphatic supplement launch reveals about evidence gaps, regulation, and risks in botanical congestion relief.
Find out how a low-dose ketamine protocol may help fentanyl users start buprenorphine faster and with less withdrawal discomfort.